Tracer library / [177Lu]Lu-NeoB

[177Lu]Lu-NeoB

Also written as [Lu-177]Lu-NeoB; [Lu-177]NeoB

Radionuclide: Lu-177 t½ 9584.6 min
Modality: Therapy
Production route: —
Stage: Clinical research
Syntheses indexed: 1

Pan-cancer / multiple tumour types Prostate cancer Dosimetry and biodistribution studies

What it is

Compound class: GRPR-targeting peptide (bombesin analog)
Target / mechanism: Gastrin-releasing peptide receptor (GRPR) antagonist/binder PMID 41344852
Clinical application: Radioligand therapy for advanced solid tumors overexpressing GRPR (e.g., gastrointestinal stromal tumors, prostate cancer, glioblastoma, breast cancer) in phase 1 first-in-human study PMID 41344852
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	—	>98%	>97%	NeoB	37584725 2023 Eur J Nucl Med Mol Imaging NeoB and RM2 were synthesized as described in Supplementary material 1. - [177Lu]Lu-NeoB and [177Lu]Lu-RM2 were obtained in > 98% RCY and > 97% RCP.

Clinical literature

Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.

Phase 1 Study of [177Lu]Lu-NeoB in Patients with Advanced Solid Tumors Overexpressing Gastrin-Releasing Peptide Receptor: Preliminary Safety and Dosimetry Results.
2026 · J Nucl Med · Prospective, multicentre · Phase I

Need this precursor?We can point you to suppliers for [177Lu]Lu-NeoB, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 4 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Stage set/updated at stage 23 from PMID 41344852: 'NeoRay is a prospective, phase 1/2a, open-label, multicenter, first-in-human study of 177Lu-NeoB.'. | Stage 30 (2026-09-18): Stage was 'phase I/IIa clinical trial (first-in-human)'; normalised to 'Clinical research', original wording kept here.